Pangyo Korea Biopark: South Korea's Premier R&D Center for Biotech Firms

November 02, 2023 09:46 PM AEDT | By EIN Presswire

Google News:

Pangyo Korea Biopark: South Korea's Premier R&D Center for Biotech Firms — Image source: EIN Presswire

Recent News

Sustainability Resource Hub: Strategies, Metrics, and Best Practices

Solar Powers a Sustainable Energy Future on Rayonier Land

Turning the Tables for Sustainable Development in India

After Fifteen Years and Fifteen Reviews, CSRHub Remains B Corp Certifi...

PANGYO, SOUTH KOREA, November 2, 2023 /EINPresswire.com/ -- Located in Pangyo Techno Valley, Korea Biopark collaborates with several global R&D companies and supports their research and development projects. Since the groundbreaking in March 2010, Korea Biopark has been the largest biotech complex in Korea with a total project cost of KRW 128 billion, two basement floors, seven above-ground floors and a gross floor area of 46,488 square meters.

The building consists of two research buildings and one laboratory building, and has amenities such as sports facilities, conference rooms, and a large auditorium. The laboratory building has a dedicated area of 1167 square meters per floor, and its load and height are designed to be suitable for the laboratories of biotech companies.

Pangyo Techno Valley is a hub for research and development representing Industry 4.0 technologies. It is home to start-ups and global conglomerates, providing an optimal R&D environment. The Korea BioPark building houses public organizations and major companies such as Korea Electronics and Telecommunications Research Institute, Korea Electronics Technology Research Institute, Korea Health Functional Food Association, GE Power Korea, Baker Hughes Korea, and LabGenomics.

Pioneering biotech firms of Korea, such as Genexin, which pioneers in creating advanced antibody fusion proteins for stubborn ailments and gene as well as stem cell treatments, Genome & Company, renowned for its microbiome medicines and targeted immuno-oncology drugs, and SeouLin Bioscience, leading in the development of viral diagnostic mechanisms, are amplifying their operations at this R&D nexus.

Both the Korea Bio Park and the Pangyo Techno Valley's R&D Center have been instrumental in the evolution of diverse firms into global powerhouses. The exemplary infrastructure of Pangyo Techno Valley aids biotech enterprises in acquiring skilled professionals. The transportation grid encompassing the Gyeongbu Expressway, Bundang-Nagok Expressway, Bundang-Suseo Expressway, and the Shinbundang DX subway ensures seamless commuting. The vicinity's educational institutions further facilitate companies in talent acquisition.

Numerous large-scale corporations are gravitating towards Pangyo Techno Valley to synergize on R&D for biotech ventures. In 2017, an influx of R&D entities from the food and chemical sectors established their bases in Pangyo. Manufacturing giants like Hanwha Vision, HD Hyundai, Korea Shipbuilding & Marine Engineering, Hanwha Aerospace, and Samsung Heavy Industries, along with heavy engineering firms, have their R&D outposts here. Internationally acclaimed game developer, NCsoft, is slated to commence its R&D facility, dubbed "Global RDI," by late 2023.

Positioned as South Korea's R&D heartland, Pangyo Technovalley aspires to mirror the prominence of Silicon Valley, amalgamating public agencies, transit systems, and corporate giants.

Vallabh Rao
TopPRWire
email us here

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.